Rallybio Corporation

RLYB

$16.88

-0.38%-$0.07

High—

Low—

52W High-4.0%

Rel. vol—

Interval

Range2.2h

Volume—SMA5SMA10

—

AI analysis

Rallybio Corporation is showing mixed intraday momentum with consolidation near key moving averages and heightened sensitivity to liquidity shifts.

Upside confirmation strengthens on sustained reclaim above short-term trend anchors.
Breakdown risk rises if support fails with accelerating sell volume.
Relative strength versus sector peers remains neutral-to-slightly positive.

Latest indicator snapshot

Live technical and fundamental context, tuned for quick reads.

SMA5

$16.97

5-period simple moving average

SMA10

$16.92

10-period simple moving average

SMA20

$16.86

20-period simple moving average

SMA50

$16.86

50-period simple moving average

EMA5

$16.96

5-period exponential moving average

EMA10

$16.93

10-period exponential moving average

EMA20

$16.89

20-period exponential moving average

DEMA20

$16.93

Double exponential moving average

Fibonacci

Retracement

Retracement levels

VWAP

$16.88

Volume weighted average price

MACD

0.038

Signal 0.020

RSI(14)

63.5

Relative strength oscillator

OBV

-362

On-balance volume

StochRSI

63.5 / 63.5

Fast oscillator pair

BBands Low

$16.67

Lower band

BBands Mid

$16.86

Middle band

BBands High

$17.06

Upper band

Market Cap

89.55M

Company size

P/E Ratio

2.09

Valuation multiple

EV / EBITDA

-1.41

Enterprise value multiple

ROE

64.9%

Return on equity

ROA

-21.3%

Return on assets

Operating Margin

-3935.0%

Operating efficiency

Net Margin

7051.0%

Bottom-line profitability

Current Ratio

—

Short-term liquidity

Debt / Equity

—

Balance-sheet leverage

Dividend Yield

0.0%

Income yield

FCF Yield

—

Free cash flow yield

Beta

-0.86

Market sensitivity

52W High

$17.57

52-week peak

52W Low

$3.67

52-week trough

Supply Chain of RLYB

Upstream / Downstream / Proxies

Upstream

Affibody ABSwedish Orphan Biovitrum AB (Sobi)STO:SOBIAbCellera Biologics Inc.NASDAQ:ABCL Recursion Pharmaceuticals (via Exscientia legacy)NASDAQ:RXRX Johnson & Johnson Innovation — JJDCNYSE:JNJUnnamed CDMO Partner(s)Unnamed CRO Partner(s)

Downstream

Johnson & Johnson (via Momenta Pharmaceuticals subsidiary)NYSE:JNJAvenzo TherapeuticsUnconfirmedRecursion PharmaceuticalsNASDAQ:RXRX

Proxies

Apellis Pharmaceuticals Inc.NASDAQ:APLS Alexion Pharmaceuticals (AstraZeneca Rare Disease)NASDAQ:AZN Recursion Pharmaceuticals Inc.NASDAQ:RXRXCandid Therapeutics Inc.Unconfirmed

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer